Dialogue Volume 10 Issue 1 2014 | Page 30

PRACTICE PARTNER Atypical antipsychotics linked with DKA in patients with Type 2 diabetes T he Patient Safety Review Committee, a committee of the Chief Coroner of Ontario, is reminding physicians of the need to consider ketoacidosis, even in patients with Type 2 diabetes mellitus, especially in those receiving atypical antipsychotic agents. The deceased was a 47-year-old male with three significant illnesses: schizophrenia, panic disorder and Type 2 diabetes mellitus (T2DM). After an incident that resulted in criminal charges and subsequent institutionalization in 2007, his schizophrenia was treated with olanzepine. The T2DM was diagnosed in January 2009 and treated with metformin 500 mg (two to three times daily) and glyburide 2.5 mg (twice daily) over time. In November 2009, the man lived in a supportive housing-type environment with daily dispensing and monitoring of medications. In November-December 2009, he was re-admitted to hospital with panic disorder; clonazepam was started and the olanzepine was switched to risperidone. During this admission, the patient continued on his diabetes medications and received further monitoring and therapy for T2DM and its complications. This included: •  ducation (he saw a dietitian November 2009, and E attended diabetes education in January 2010); •  onitoring for glycemic control – (this showed M suboptimal control with hemoglobin A1C 7.6% (ideal<7%) on December 3, 2009); •  creening for complications (he had undetectable S urinary microalbumin levels and eyes screened in February 2010); and •  reatment of additional cardiovascular risk factors T (he was started on rosuvastatin in December 2009 for hypercholesterolemia). Reports from December 2009 indicate that he blamed the symptoms of his panic attacks (i.e., abnormal pacing, panic, fear that he was having a heart attack) on his diabetes medications. He was readmitted to hospital from May 11-June 28, 2010 with worsening psychosis. His risperidone was switched to clozapine and he was taking metformin and glyburide with well-controlled DM (A1C 6.8%). An elevated insulin level confirmed the diagnosis was Type 2 DM and not Type 1 DM. After discharge from hospital in late June 2010, the patient was again living in the community and was seen two to three times weekly by the nurse or social worker. On September 27, 2010 he is noted to have been assessed by a psychiatry resident. Glycemic control deteriorated dramatically by November 22, 2010 when his general practitioner noted that his A1C was now 14.3% and plasma glucose was 32 (normal random <11 mMol/L). Electrolytes and anion gap were not mentioned. At the time, the patient indicated that he had stopped taking the diabetes medications because he was following a better diet at home. His weight had decreased to 75 kg. Subsequent nurse and physician notes indicated that the patient would not allow monitoring of his diabetes laboratory values or take diabetes medication despite many warnings and offers of assistance. On February 13, 2012, the patient did not show up for his medication check-up and was subsequently found Continued on page 33... 32 DIALOGUE • Issue 1, 2014